CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 151 enrolled
Drug / intervention
Dual x-ray absorptiometry (DXA) +2 moreprocedure
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00603967
NCT00603967N/ACompleted
CompareCT.gov

Aromatase Inhibitors: Skeletal Effects and the Role of CYP19 Gene Polymorphisms

Washington University School of Medicine·interventional·Posted Jan 29, 2008·Updated May 24, 2013

In Brief

A clinical study evaluating Dual x-ray absorptiometry (DXA), Blood draw, and 1 other intervention for Breast Cancer and Postmenopausal. Completed, enrolled 151 participants across 1 site.

Detailed Summary

The primary objective of this 2-year pilot project is to test the hypothesis that skeletal response to aromatase inhibitors is determined by polymorphisms of the CYP19 gene.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer, Postmenopausal
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 29, 2008
Enrollment StartMar 1, 2006
Primary CompletionOct 1, 2009
TodayJul 2, 2026
Enrollment to primary: 3.6 yearsPosted 18.4 years ago

Interventions

Dual x-ray absorptiometry (DXA)procedure

Baseline, 6 months, and 12 months

Blood drawprocedure

Baseline - genotyping Baseline, 6 months, and 12 months - markers of bone turnover and hormonal assays

Questionnairebehavioral

Menopausal symptom questionnaire - baseline, 3 months, 6 months, 12 months Cognitive tests - baseline, 6 months, 12 months Depression assessment - baseline, 6 months, 12 months Dietary calcium intake questionnaire - baseline